Granules India CEO K V Sitaram Rao resigns
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
The inspection was conducted from July 22-25, 2025
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
The company has made an investment of Rs. 565.40 crore in DRL Russia for a total equity stake of 45.19%
This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies
The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs
The company received one observation in the Form-483
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
Subscribe To Our Newsletter & Stay Updated